Allston, MA – According to filings with the U.S. Securities and Exchange Commission, Manifold Bio is raising $39,999,985.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gleb Kuznetsov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Manifold Bio
The pace of drug discovery is limited by the complexity of biology. In vivo models provide the most predictive measurements, but are often restricted by their fundamentally low throughput capability. At Manifold Bio, we’ve created a platform called M-Design that can be used to bring high throughput measurements to the most translationally predictive environments. This process allows us to track multiple key properties of drug development within the same in vivo model, unlocking the power of multiplexed measurements in the field of protein therapeutics. To pursue our mission, we are leveraging our teams unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. And we are looking to bring on more folks that are excited about the potential for this entirely new way of engineering biology.

To learn more about Manifold Bio, visit http://www.manifold.bio/

Contact:
Gleb Kuznetsov, Chief Executive Officer
801-244-4494
gleb@manifold.bio
https://www.linkedin.com/in/gleb-kuznetsov/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved